Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Catanzaro, A
Right arrow Articles by Friedman, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Catanzaro, A
Right arrow Articles by Friedman, P.

Chest, Vol 97, 666-669, Copyright © 1990 by American College of Chest Physicians

ARTICLES

Fluconazole in the treatment of persistent coccidioidomycosis

A Catanzaro, J Fierer and PJ Friedman
Department of Pulmonary and Critical Care Medicine, University of California, San Diego Medical Center.

Fluconazole is one of the new antifungal triazoles undergoing clinical trials. We used fluconazole at a dose of 50 or 100 mg/day in an open trial for the treatment of patients with persistent coccidioidomycosis. Fourteen patients were enrolled and treated for a mean of 13 +/- 7 months. Two failed to respond. Of the 12 who responded, one reactivated while being treated, and one died of myocardial infarction after successful treatment of his fungal infection; six had relapses from nine days to 15 months after treatment was stopped. Only four patients are asymptomatic at a mean of 14 +/- 3 months after cessation of treatment. Fluconazole is well tolerated at this dose. In view of its low toxicity, the partial clinical efficacy observed, and the high recurrence rate of chronic coccidioidal infection, it would be justified to try higher doses.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
J. N. Galgiani, A. Catanzaro, G. A. Cloud, R. H. Johnson, P. L. Williams, L. F. Mirels, F. Nassar, J. E. Lutz, D. A. Stevens, P. K. Sharkey, et al.
Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis: A Randomized, Double-Blind Trial
Ann Intern Med, November 7, 2000; 133(9): 676 - 686.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Como and W. E. Dismukes
Oral Azole Drugs as Systemic Antifungal Therapy
N. Engl. J. Med., January 27, 1994; 330(4): 263 - 272.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Chest Physicians.